Endostar-loaded PEG-PLGA nanoparticles: In vitro and in vivo evaluation

International Journal of Nanomedicine

Volumn 5, Issue 1, 2010, Pages 1039-1048

  Hu, Sanyuan ^a   Zhang, Yangde ^b  

^a The First People s Hospital of Changde City)   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Biologic physics; Medical physics; Nanoparticles

Indexed keywords

ENDOSTAR; MACROGOL; NANOCARRIER; POLYGLACTIN; RECOMBINANT ENDOSTATIN; UNCLASSIFIED DRUG; ENDOSTAR PROTEIN; ENDOSTATIN; MACROGOL DERIVATIVE; NANOPARTICLE; POLY(LACTIC GLYCOLIC ACID) POLY(ETHYLENEGLYCOL) COPOLYMER; POLY(LACTIC-GLYCOLIC ACID)-POLY(ETHYLENEGLYCOL) COPOLYMER; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HT29; COLON CANCER; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NANOENCAPSULATION; NONHUMAN; PHOTON CORRELATION SPECTROSCOPY; PLASMA CONCENTRATION-TIME CURVE; RABBIT; TISSUE DISTRIBUTION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR GROWTH; WESTERN BLOTTING; ANALYSIS OF VARIANCE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL PROLIFERATION; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; NEOPLASM; NUDE MOUSE; PARTICLE SIZE; PATHOLOGY;

MUS; MUS MUSCULUS; ORYCTOLAGUS CUNICULUS;

ANALYSIS OF VARIANCE; ANIMALS; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; ENDOSTATINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; NEOPLASMS; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLACTIN 910; RABBITS; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79954470630     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S14753     Document Type: Article

References (36)

1. Michor F, Iwasa Y, Lengauer C, Nowak MA. Dynamics of colorectal cancer. Semin Cancer Biol. 2005;15(6):484-493.
2. Nishiyama N, Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther. 2006;112(3):630-648.
3. Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 2007;9(2):E128-E147.
4. Jun YJ, Kim JI, Jun MJ, Sohn YS. Selective tumor targeting by enhanced permeability and retention effect. Synthesis and antitumor activity of polyphosphazene-platinum (II) conjugates. J Inorg Biochem. 2005;99(8):1593-1601.
5. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines. J Drug Target. 2007;15(7-8):457-464.
6. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006;11(17-18):812-818.
7. Wang C, Pham PT. Polymers for viral gene delivery. Expert Opin Drug Deliv. 2008;5(4):385-401.
8. Ling Y, Yang Y, Lu N, et al. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun. 2007;361(1):79-84.
9. Zhuo W, Luo C, Wang X, Song X, Fu Y, Luo Y. Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells. J Pathol. 2010;222(3):249-260.
10. Song HF, Liu XW, Zhang HN, et al. Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys. Acta Pharmacol Sin. 2005;26(1):124-128.
11. Jiang LP, Zou C, Yuan X, et al. N-terminal modification increases the stability of the recombinant human endostatin in vitro. Biotechnol Appl Biochem. 2009;54(2):113-120.
12. Cohen S, Yoshioka T, Lucarelli M, Hwang LH, Langer R. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res. 1991;8(6):713-720.
13. Roy A, Singh MS, Upadhyay PK, Bhaskar S. Combined chemoimmunotherapy as a prospective strategy to combat cancer: A nanoparticle based approach. Mol Pharm. 2010 Sep 16. [Epub ahead of print].
14. Mukherjee B, Santra K, Pattnaik G, Ghosh S. Preparation, characterization and in-vitro evaluation of sustained release protein-loaded nanoparticles based on biodegradable polymers. Int J Nanomedicine. 2008;3(4):487-496.
15. Gref R, Quellec P, Sanchez A, et al. Development and characterization of CyA-loaded poly(lactic acid)-poly(ethylene glycol)PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers. Eur J Pharm Biopharm. 2001;51(2):111-118.
16. Thomas JP, Arzoomanian RZ, Alberti D, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2003;21(2):223-231.
17. Tentler JJ, Bradshaw-Pierce EL, Serkova NJ, et al. Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clin Cancer Res. 2010;16(11): 2989-2998.
18. Jie JZ, Wang JW, Qu JG, Hung T. Suppression of human colon tumor growth by adenoviral vector-mediated NK4 expression in an athymic mouse model. World J Gastroenterol. 2007;13(13):1938-1946.
19. Gao J, Knutsen A, Arbman G, et al. Clinical and biological significance of angiogenesis and lymphangiogenesis in colorectal cancer. Dig Liver Dis. 2009;41(2):116-122.
20. Wu J, Wu L, Xu X, et al. Microspheres made by w/o/o emulsion method with reduced initial burst for long-term delivery of endostar, a novel recombinant human endostatin. J Pharm Sci. 2009;98(6):2051-2058.
21. Li Y, Pei Y, Zhang X, et al. PEGylated PLGA nanoparticles as protein carriers: Synthesis, preparation and biodistribution in rats. J Control Release. 2001;71(2):203-211.
22. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci U S A. 1998;95(8):4607-4612.
23. Son S, Lee WR, Joung YK, et al. Optimized stability retention of a monoclonal antibody in the PLGA nanoparticles. Int J Pharm. 2009;368(1-2):178-185.
24. Mandal D, Chatterjee U. Synthesis and spectroscopy of CdS nanoparticles in amphiphilic diblock copolymer micelles. J Chem Phys. 2007;126(13):134507.
25. Arimura H, Ohya Y, Ouchi T. Formation of core-shell type biodegradable polymeric micelles from amphiphilic poly(aspartic acid)-block-polylactide diblock copolymer. Biomacromolecules. 2005;6(2):720-725.
26. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res. 2010;62(2):90-99.
27. Li SD, Huang L. Nanoparticles evading the reticuloendothelial system: Role of the supported bilayer. Biochim Biophys Acta. 2009;1788(10):2259-2266.
28. Jeong YI, Kang MK, Sun HS, et al. All-trans-retinoic acid release from core-shell type nanoparticles of poly(epsilon-caprolactone)/ poly(ethylene glycol) diblock copolymer. Int J Pharm. 2004; 273(1-2): 95-107.
29. Zhang X, Pan SR, Hu HM, et al. Poly(ethylene glycol)-block- polyethylenimine copolymers as carriers for gene delivery: Effects of PEG molecular weight and PEGylation degree. J Biomed Mater Res A. 2008;84(3):795-804.
30. Muthu M. Nanoparticles based on PLGA and its co-polymer: An overview. Asian J Pharm. 2009;3(4):266-273.
31. Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760.
32. Wang MD, Shin DM, Simons JW, Nie S. Nanotechnology for targeted cancer therapy. Expert Rev Anticancer Ther. 2007;7(6): 833-837.
33. Petros RA, de Simone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615-627.
34. Kisker O, Becker CM, Prox D, et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 2001;61(20):7669-7674.
35. Xu F, Ma Q, Sha H. Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment. Crit Rev Ther Drug Carrier Syst. 2007;24(5):445-492.
36. Ling Y, Lu N, Gao Y, et al. Endostar induces apoptotic effects in HUVECs through activation of caspase-3 and decrease of Bcl-2. Anticancer Res. 2009;29(1):411-417.